- Kashiv BioSciences and JAMP Pharma have commercially launched Pexegra and Filra, biosimilar alternatives to Neulasta and Neupogen respectively, in the Canadian market. - Both biosimilars are indicated for treating neutropenia in cancer patients undergoing chemotherapy, with Pexegra reducing infection incidence and Filra addressing severe neutropenia conditions. - The launch marks JAMP Pharma's entry into oncology biosimilars through its BioJAMP division, expanding treatment options for Canadian patients. - The products are available as pre-filled syringes with safety features and represent part of JAMP's commitment to providing affordable biosimilar alternatives in Canada.

Sep 25, 2025

返回机构列表

Jamp Pharma Corporation

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（6）

A clinical study to test a Diclofenac Gel in comparison with another reference gel and an inert gel for Pain Relief and Safety in Fresh Outer Ankle Sprains (ankle twists)

To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitis

To evaluate the efficacy and tolerability of diclofenac diethylamine 1.16% w/w gel in patients with acute localised muscle or joint injuries

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

To understand the safety and outcome of Tacrolimus ointment 0.1% in patients suffering from Atopic dermatitis

To evaluate the efficacy and tolerability of diclofenac diethylamine 1.16% w/w gel in patients with acute localised muscle or joint injuries

药物批准

按机构分类的批准

近期批准

资讯

Kashiv BioSciences and JAMP Pharma Launch Neutropenia Biosimilars in Canada